Related Experiment Video
Updated: Jun 19, 2026
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Salmeterol/fluticasone combination in COPD: is together better?
Sabina A Antoniu1, Irina Mititiuc
1Clinic of Pulmonary Disease, University of Medicine and Pharmacy 'Gr.T.Popa' Iasi, 30 Dr I Cihac Str., 6600 Iasi, Romania. sabinaantoniu@excite.com
Expert Review of Pharmacoeconomics & Outcomes Research
|October 8, 2009
Summary
Inhaled therapies, including bronchodilators and steroids, help manage chronic obstructive pulmonary disease (COPD) symptoms. Combining salmeterol and fluticasone offers a potentially more effective inhalatory treatment option for COPD patients.
Area of Science:
- Pulmonology
- Pharmacology
Background:
- Chronic obstructive pulmonary disease (COPD) management involves various inhalatory therapies targeting symptom relief.
- Bronchodilators (e.g., salmeterol, formoterol) and inhaled corticosteroids (e.g., budesonide, fluticasone) are established COPD treatments.
- Combination therapies aim to enhance treatment efficacy for COPD patients.
Discussion:
- This analysis evaluates the clinical effectiveness of the salmeterol/fluticasone combination therapy.
- The study focuses on short-term clinical outcomes in COPD patients.
- Inhalatory route is a primary delivery method for COPD medications.
Key Insights:
- Salmeterol/fluticasone combination therapy demonstrates clinical effectiveness in managing COPD.
- Key outcomes assessed include symptom reduction and lung function.
- Combined inhalatory treatments may offer improved therapeutic benefits.
Outlook:
- Further research is warranted to explore long-term efficacy and safety profiles.
- Optimizing combination inhalatory therapy could improve patient health status.
- Investigating personalized treatment approaches for COPD is crucial.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:23Inhaled Medications
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation